Introduction Standard treatment for locally advanced cervical cancer (LACC) includes
concomitant chemoradiotherapy (CRT) that typically controls localized disease. However …

Aims: With the use of concurrent chemoradiotherapy (CCRT) for locally advanced cervical
cancer (LACC), survival outcomes are still not optimal. This study was designed to evaluate …

PURPOSE Although chemoradiation therapy (CRT) with cisplatin remains the standard
treatment of patients with locally advanced cervical cancer (LACC), 40% of patients present …

Objective To compare response rate and survivals of locally advanced stage cervical cancer
patients who had standard concurrent chemoradiation therapy (CCRT) alone to those who …

OBJECTIVE: To evaluate role of dose dense neo-adjuvant chemotherapy (NACT) prior to
standard concurrent chemo-radiation (CCRT) in locally advanced cervical cancer …

Background To evaluate the benefit with the addition of paclitaxel to cisplatin-based
concurrent chemoradiotherapy (C-CRT) for the treatment of locally advanced carcinoma of …

Objective: To evaluated the oncologic outcomes associated with platinum-based adjuvant
chemotherapy following concurrent chemoradiotherapy (CCRT) in the management of …

Aim Neoadjuvant chemotherapy represents a promising alternative to concomitant chemo-
radiation therapy in locally advanced cervical cancer patients. The aim of this study was the …

Background Currently, the standard treatment for locally advanced cervical cancer is
concurrent chemoradiation (CCRT). Forty percent of patients present with disease …

Methods We prospectively enrolled surgically staged patients with positive peritoneal
cytology, resectable nodal metastases, or primary tumor> 6 cm. Patients were treated using …